Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY4R | P50391 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113544 | 1.00 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21322478 | 1.00 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15626074 | 0.94 | FOLH1 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL278813 | 0.94 | FOLH1 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25637037 | 0.93 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25973099 | 0.92 | FURIN (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21322755 | 0.91 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13348009 | 0.91 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21160523 | 0.90 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25637039 | 0.90 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11753464-B2 | Methods and compositions for targeting polyubiquitin | GENENTECH, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3408271-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3498301-A1 | KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-3134124-B1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-10035849-B2 | Methods and compositions for targeting polyubiquitin | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180201679-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | GENENTECH, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090226465-A1 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | GENENTECH, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035849-B2 | Methods and compositions for targeting polyubiquitin | PSMG3, STUB1, USP47 | HDAC3 1656/4885HDAC4 3468/4885HDAC1 2322/4885 |
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | STXBP1, WASF2, SDAD1 | HDAC3 4652/4885HDAC4 4079/4885HDAC1 4472/4885 |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | HDAC3 2051/4885HDAC4 1848/4885HDAC1 1679/4885 |
| US-20180201679-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | HDAC3 2684/4885HDAC4 3299/4885HDAC1 2898/4885 |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | PCTP, LNPEP, SLC3A2 | HDAC3 4681/4885HDAC4 4526/4885HDAC1 4590/4885 |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | PSMG3, STUB1, USP47 | HDAC3 1656/4885HDAC4 3468/4885HDAC1 2322/4885 |
| US-11753464-B2 | Methods and compositions for targeting polyubiquitin | PSMG3, STUB1, USP47 | HDAC3 1656/4885HDAC4 3468/4885HDAC1 2322/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | HDAC3 1909/4885HDAC4 3629/4885HDAC1 3609/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | HDAC3 2990/4885HDAC4 3573/4885HDAC1 3326/4885 |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | MUC1, PDIA6, LNPEP | HDAC3 4817/4885HDAC4 4512/4885HDAC1 4665/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | HDAC3 4454/4885HDAC4 3751/4885HDAC1 3306/4885 |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | HDAC3 2684/4885HDAC4 3299/4885HDAC1 2898/4885 |
| US-20090226465-A1 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | APLNR, APMAP, CD22 | HDAC3 1324/4885HDAC4 1553/4885HDAC1 796/4885 |
| US-20080247951-A1 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR | IGSF11, MRPS18A, ANXA4 | HDAC3 3994/4885HDAC4 3747/4885HDAC1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.